Tickers

1. Composite Trajectory Verdict

All three statements carry weight: the income statement shows the operating performance of the three remaining segments, the cash flow statement reveals the cash conversion of that performance and the impact of separation-related outflows, and the balance sheet reflects the significant debt reduction and equity restoration since the spin-off.

Composite Trajectory: Mixed

Revenue trends are improving on an organic basis (3.3% FY2025, 5.8% H1 2026, 9.5% Q2 2026), but segment operating income margins have compressed over three years (MedSurg 23.9% → 19.1% → 16.8%; Dental 33.3% → 27.0% → 25.6%). Total operating income rose 110.5% in FY2025 only because of a $1.5B gain on the Purification and Filtration sale; excluding that gain, operating income would have declined. Operating cash flow has fallen each year ($1,915M FY2023 → $1,185M FY2024 → $369M FY2025 → $38M H1 2026). The balance sheet improved through FY2025 with debt cut from $8.2B to $5.0B and equity rising from $3.0B to $5.0B, but cash dropped from $878M to $403M in H1 2026 while receivables jumped 27%.

2. Red Flags

• Operating cash flow declined 81% year-over-year in FY2025 ($369M vs $1,185M) and a further 81% in H1 2026 vs H1 2025 ($38M vs $198M) (10-K FY2025, Consolidated Statements of Cash Flows; 10-Q Q2 2026, Condensed Statements of Cash Flows)
• Corporate and Unallocated expense widened sharply: -$778M in H1 2026 vs -$543M in H1 2025, and -$736M in FY2024 vs -$442M in FY2023 (10-K FY2025, Segment Operating Income table; 10-Q Q2 2026, Segment Operating Income table)
• Accounts receivable surged 27% to $1.31B at June 30, 2026 from $1.03B at Dec 31, 2025, outpacing the 2.2% reported sales growth in Q2 2026 (10-Q Q2 2026, Condensed Balance Sheets; 10-Q Q2 2026, Segment Net Sales table)
• SG&A as a percent of sales rose to 42.0% in Q2 2026 from 35.7% in Q2 2025 and 37.0% in FY2025 from 33.7% in FY2024 (10-Q Q2 2026, Operating Expenses table; 10-K FY2025, Operating Expenses table)
• MedSurg segment operating margin fell from 23.9% (FY2023) to 19.1% (FY2024) to 16.8% (FY2025) despite positive organic growth each year (10-K FY2025, MedSurg segment table)

3. Earnings Assessment (Income Statement)

Earnings Trajectory: Mixed

Total net sales grew modestly in FY2025 (+0.9% to $8.325B) and were flat in H1 2026 (-0.4% to $4.216B), but organic growth accelerated to 3.3% (FY2025), 5.8% (H1 2026), and 9.5% (Q2 2026) (10-K FY2025, Segment Net Sales table; 10-Q Q2 2026, Segment Net Sales tables). Segment operating income for the three ongoing segments combined was $1.652B in FY2025 vs $1.668B in FY2024 vs $1.972B in FY2023, showing a three-year decline (10-K FY2025, Business Segment Information). MedSurg operating margin fell from 23.9% to 16.8% over that span; Dental from 33.3% to 25.6%; Health Information Systems improved from 32.9% to 36.5% (10-K FY2025, segment tables). FY2025 net income of $1.556B included a $1.549B gain on the Purification and Filtration sale; without it, net income would have been near $7M (10-K FY2025, Consolidated Statements of Operations). In H1 2026, total operating income fell 28.6% to $262M despite segment operating income rising 21-24% each, because Corporate and Unallocated expense increased 43% to $778M (10-Q Q2 2026, Segment Operating Income table).

4. Cash Generation Assessment (Statement of Cash Flows)

Cash Trajectory: Deteriorating

Operating cash flow has declined in each of the last three annual periods: $1.915B (FY2023) → $1.185B (FY2024) → $369M (FY2025) (10-K FY2025, Consolidated Statements of Cash Flows). In the first six months of 2026 it fell further to $38M vs $198M in H1 2025 (10-Q Q2 2026, Condensed Statements of Cash Flows). The FY2025 decline was attributed to lower net income excluding the divestiture gain, higher separation costs, and higher receivables and other assets for transition service agreements (10-K FY2025, Operating Activities). H1 2026 decline was driven by higher annual incentive compensation payments and payments to exit transition agreements with 3M (10-Q Q2 2026, Operating Activities). Investing cash flow turned positive in FY2025 ($2.797B) due to $3.89B proceeds from the Purification and Filtration sale, partially offset by $696M for the Acera acquisition (10-K FY2025, Investing Activities). Financing cash outflows were $3.057B in FY2025, primarily $3.07B debt repayment (10-K FY2025, Financing Activities). In H1 2026, financing outflows of $350M included $288M (Q2) and $355M (H1) for share repurchases (10-Q Q2 2026, Financing Activities).

5. Balance Sheet Assessment

Balance Sheet Trajectory: Mixed

Total debt was reduced from $8.21B at Dec 31, 2024 ($8.01B long-term + $200M current) to $5.035B at Dec 31, 2025 (all long-term) and further reduced in H1 2026 (10-K FY2025, Long-Term Debt table; 10-Q Q2 2026, Condensed Balance Sheets). Total equity rose from $2.959B to $5.049B over FY2025, driven by $1.556B net income and $430M other comprehensive income (10-K FY2025, Consolidated Statements of Changes in Equity). Cash and equivalents fell from $878M at Dec 31, 2025 to $403M at June 30, 2026 (10-K FY2025, Consolidated Balance Sheets; 10-Q Q2 2026, Condensed Balance Sheets). Accounts receivable increased 27% to $1.31B at June 30, 2026 from $1.03B at Dec 31, 2025 (10-Q Q2 2026, Condensed Balance Sheets). Goodwill decreased from $6.377B to $5.704B in FY2025 due to $1.391B divestiture of Purification and Filtration goodwill, partially offset by $441M from the Acera acquisition (10-K FY2025, Note 4 Goodwill table). Property, plant and equipment rose to $1.565B at June 30, 2026 from $1.326B at Dec 31, 2025, reflecting a finance lease for the new Eagan headquarters (10-Q Q2 2026, Condensed Balance Sheets; 10-Q Q2 2026, Note 13 Leases).

6. Data Gaps

• Q1 2026 standalone income statement and cash flow figures (to separate Q2 from H1 trends) — would require the 10-Q for period ended March 31, 2026
• Q3 2025 and Q4 2025 standalone quarterly results — would require the 10-Q for period ended September 30, 2025 and the 10-K's quarterly breakdown
• Full June 30, 2026 balance sheet (long-term debt, total liabilities, total equity) — the provided 10-Q XBRL data was truncated
• Organic growth rate for FY2023 (to complete the three-year organic trend) — not explicitly disclosed in the FY2025 10-K for the total company
• Free cash flow (operating cash flow minus capex) for each period — capex shown but not combined into a single FCF metric in the filings